Vivanza Biosciences Ltd (VIVANZA) is currently trading at 1.47 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vivanza Biosciences Limited is a pharmaceutical company focusing on both novel and generic pharmaceutical products. Established in 1982, it has faced challenges but rebranded to expand its market reach globally. The company has undertaken a significant capacity expansion project, tripling its production capabilities from 18 lac pa to 54 lac pa. Vivanza Biosciences conducted a public issue to raise funds for expansion, showcasing strategic growth ambitions. The acquisition of Vivanza Lifesciences Private Limited marks a strategic step in enhancing its product portfolio and market reach.

Over the past 52 weeks, Vivanza Biosciences Ltd has traded between a low of ₹1.30 and a high of ₹2.72. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vivanza Biosciences Ltd has a market capitalization of approximately 5.88. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vivanza Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 147.00 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 5.88 Cr, Vivanza Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vivanza Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vivanza Biosciences Ltd is 147.00. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Vivanza Biosciences reported consolidated profit for the period of Rs 13.64 lakh for the quarter ended 30 September 2026. The figure was Rs 56.29 lakh in the quarter ended 30 September 2025. Basic and diluted earnings per share were Rs 0.03, compared with Rs 0.14 a year earlier.

Vivanza Biosciences cited unavoidable circumstances for moving the meeting from November 3 to November 6, 2026. The disclosure does not provide further details about the reason.